

# Relation of Vascular Endothelial Growth Factor and Insulin Like Growth factor-1 to the Development of Retinopathy in Premature Infants

# **Thesis**

Submitted for Fulfillment of Ph.D. in Childhood Studies (Child Health and Nutrition)

Medical Studies Department

# By Rania Nabil Mohamed Sabry

M.B.B.Ch/ M.S Pediatrics Cairo University

Supervised by

# Prof. Dr. Rehab Abdel-Kader Mahmoud

Professor of Pediatrics
Department of Medical Studies
Institute of Postgraduate Childhood Studies
Ain Shams University

### Prof. Dr. Gloria Gameel Sidhom

Professor of Clinical Pathology Department of Clinical Pathology National research Center


# Prof. Dr. Inas Raafat Abdel-Hamid

Professor of Child Health Department of Child Health National research Center

### Dr. Ihab Saad Othman

Ass. Professor of Ophthalmology Department of Ophthalmology Faculty of Medicine Cairo University

Ain Shams University 2010



#### ACKNOWLEDGEMENT

I wish to express my deepest gratitude to Prof. Dr. Rehab Abd El- Kader Mahmoud, Professor of Pediatrics, Institute of Post Graduate childhood Studies, Ain Shams University for her continuous encouragement, patience and help throughout the study.

Grateful acknowledgement to Prof. Dr. Inas Raafat Abdel Hamid, Professor of Child Health, Department of Child Health, National research Center for her continuous support and help.

Special thanks, appreciation and respect to Dr. Ihab Saad Othman, Associate Professor of Ophthalmology, Cairo University, for his patience and support. Dr. Ihab Saad Othman carried out all the ocular examination throughout the study with a lot of interest and care.

I would like to thank Prof. Dr. Azza Gabre, Professor of Child Health, Department of Child Health, National Research Center, for her great help.

I am grateful to Prof. Dr. Gloria Gameel Sidhom, Professor of Clinical Pathology, National Research Center, for her helpful advises and support. Prof. Dr. Gloria carried out the entire laboratory works included in the thesis.

I would also like to express my thanks to all staff members of Almaza Charity Neonatal Unit, for providing all the cases in the study.

I am also grateful to the babies included in the study and their families.

Finally, I must thank my family for their support, encouragement and help.

### **LIST OF CONTENTS**

A CVANONIA ED CENTENT	Page 
ACKNOWLEDGEMENT	
LIST OF CONTENTS	
LIST OF TABLES	
LIST OF FIGURES	
LIST OF ABBREVIATIONS	
ABSTRACT	1
INTRODUCTION	2
REVIEW OF LITERATURE	4
THE PREMATURE INFANT	4
THE EYE	13
RETINOPATHY OF PREMATURITY	21
INSULIN-LIKE GROWTH FACTORS (IGFS) (SOMATOMEDINS)	44
INSULIN LIKE GROWTH FACTOR BINDING PROTEINS (IGF-BPS)	49
VASCULAR ENDOTHELIAL GROWTH FACTOR	58
The VEGF Isoforms:	59
The VEGF Receptors:	60
Role of VEGF in Eye:	62
Role of VEGF in Retinopathy of Prematurity:	63
PATIENTS AND METHODS	68
RESULTS	74
DISCUSSION	91
SUMMARY	97
CONCLUSIONS	99
RECOMMENDATIONS	100
REFERENCES	101
APPENDIX 1 – NICU SHEET	124
APPENDIX 2 –MASTER SHEET	127
APPENDIX 3 – PATIENT SHEET FOR RETINOPATHY OF PREMATURITY	128
الملخص العربي	129

### LIST OF TABLES

		Page
Table 1.	High-risk infants	6
Table 2.	Complications associated with preterm labor	10
Table 3.	Neonatal problems associated with premature infants	11
Table 4.	Anatomical and physiological particularities of premature eye	20
Table 5.	Timing of first eye examination based on GA at birth	37
Table 6.	ETROP classification	39
Table 7.	Sex distribution of cases and controls	74
Table 8.	Sex distribution of cases (Stage 1 and 2 versus stage 3 and 5)	75
Table 9.	Comparison of neonatal anthropometric data between cases and	75
	controls	
Table 10.	Neonatal anthropometric data of cases (Stage 1 and 2 versus	79
	stage 3 and 5)	
Table 11.	Risk factors for ROP in cases and controls	80
Table 12.	Comparison of some clinical data between cases and controls	81
Table 13.	Clinical data of cases (Stage 1 and 2 versus stage 3 and 5)	82
Table 14.	Comparison of cytokine serum levels between cases and controls	83
Table 15.	Cytokine levels of cases (stage 1 & 2 versus stage 3 & 5)	84
Table16.	Multivariate logistic regression of the effects of the variables on	85
	ROP	
Table 17	Sensitivity and specificity values for IGF-1 and VEGF.	85
Table 18.	Correlations between IGF-1 and neonatal clinical data	86
Table 19.	Correlations between IGF-1 and data concerning oxygen	88
	administration	
Table 20.	Correlations between VEGF and neonatal clinical data	88
Table 21.	Correlation between VEGF and data concerning oxygen	88
	administration	
Table 22.	Correlation between IGF-1 and VEGF	89

# LIST OF FIGURES

		Page
Figure 1	The New Ballard Scoring system	8
Figure 2	The eye at different stages of development	14
Figure 3	Diagrams showing the development of the ciliary body and iris	16
(A, B)		
Figure 4	Schematic drawing of zones of ROP	24
Figure 5	Stage 1 ROP with demarcation line	25
Figure 6	Stage 2 ROP consisting of a ridge	25
Figure 7	Stage 3 ROP consisting of a ridge with extra retinal fibrovascular	26
	proliferation	
Figure 8	Stage 4 ROP tractional retinal detachment	27
Figure 9	Plus disease in ROP	27
Figure 10	Rush Disease	28
Figure 11	Regressed ROP	29
Figure 12	Color fundus photograph showing post laser ablation of the	41
	avascular retina	
Figure 13	Structure of long IGF-1 molecule	46
Figure 14	Domain structure and homlogy of Insulin receptor and IGF-I	48
	receptor	
Figure 15	The Insulin-like growth factors, their receptors, and their binding	49
	proteins	
Figure 16	Schematic representation of the distinct binding of the members	59
	of the VEGF family to the 3 VEGF receptors	
Figure 17	Molecular structure of the VEGF receptors	60
Figure 18	VEGF model of pathophysiology of ROP	64
Figure 19	Retcam 2 device	70
Figure 20	Sex distribution of cases and controls	74
Figure 21	Mean gestational age of cases and controls	76
Figure 22	Mean birth weight of cases and controls	76
Figure 23	Mean weight of cases and controls	77
Figure 24	Mean length of cases and controls	77

Figure 25	Mean head circumference of cases and controls	78
Figure 26	Neonatal anthropometric data of cases (stage 1 and 2 versus stage	79
	3 and 5)	
Figure 27	Median duration of stay in NICU for cases and controls	80
Figure 28	Risk factors for ROP in cases and controls	81
Figure 29	Comparison of some clinical data between cases and controls	82
Figure 30	Percentage distribution of cases between stage 1, 2, 3, and 5	83
Figure 31	Comparison of cytokine serum levels between cases and controls	84
Figure 32	Correlation between IGF-1 and Weight at Examination	86
Figure 33	Correlation between IGF-1 and Length	87
Figure 34	Correlation between IGF-1 and Head Circumference	87
Figure 35	Wide angle digital fundus image of the left eye for one of the	89
	cases showing zone 1 posterior ROP with Plus Disease. Zone 1	
	Stage 3 ROP	
Figure 36	Wide angle digital fundus image of the left eye for the same case	90
	focused on supero temporal fibro vascular frond with	
	neovascularization and peripheral ischaemic retina	
Figure 37	Wide angle digital fundus image of the left eye for the same case	90
	three days post avastin injection and laser to the retinal periphery	
	showing less dilatation and torsiousity of retinal vessels	

#### LIST OF ABBREVIATIONS

AGA : Appropriate gestational age

ALS : Acid labile subunit

AAP : American academy of pediatrics

AP-ROP : Aggressive posterior retinopathy of prematurity

bFGF : Basic fibroblast growth factor

BP : Blood pressure

BPD : Broncho pulmonary dysplasia

BUN : Blood urea nitrogen

BW : Birth weight

CBC : Complete blood count

ChBF : Chroidal blood flow

CO<sub>2</sub> : Carbon Dioxide

CRP : C-reactive protein

Cryo ROP : Cryotherapy for retinopathy of prematurity

CSF : Cerebrospinal fluid

DOB : Date of birth

EEG : Electroencephalogram

EGF : Epidermal growth factor

ELBW : Extreme low birth weight

ESR : Erythrocyte sedimentation rate

ETROP : Early treatment retinopathy of prematurity

FDP : Fibrin degradation products

FGF : Fibroplast growth factor

FiO<sub>2</sub> : Flow of inspired oxygen

Flt-1 : Fms-related tyrosine kinase-1

GA : Gestational age

GH : Growth hormone

GHD : Growth hormone deficiency

HC : Head circumference

HR : Heart rate

hGH : Human growth hormone

IGF : Insulin like growth factor

#### **Abbreviations**

IGFBP : Insulin like growth factor binding protein

IOP : Intraocular pressure

IRBP : Interstitial retinal binding protein

IUGR : Intra uterine growth retardation

IVH : Intraventricular hemorrhage

kDa : Kilodaltons

KDR : Kinase insert domain receptor

LBW : Low birth weight

LOC : Level of consciousness

MSA : Multiplication stimulating factor

MW : Molecular weight

NBS : New Ballard Score

NCPAP : Nasal continuous positive airway pressure

ng : Nanogram

NICU : Neonatal intensive care unit

NJ : Neonatal jaundice

NS : Neonatal sepsis

NSILA : Non suppressible insulin like activity

PaCO<sub>2</sub> : Partial arterial CO<sub>2</sub> tension

PaO<sub>2</sub> : Partial arterial oxygen tension

PDA : Patent ductus arteriosis

PDGF : Platelet derived growth factor

pg : Picogram

PGE<sub>2</sub>: Prostaglandin E<sub>2</sub>

PN : Post natal

PT : Prothrombin time

PTT : Partial thromboplastin time

PUFAS : Poly unsaturated fatty acid

RBF : Retinal blood flow

RDS : Respiratory distress syndrome

RLF :Retrolental fibroplasias

ROP : Retinopathy of prematurity

RPE : Retinal pigment epithelium

RR : Respiratory rate

#### **Abbreviations**

SD : Standard deviation

SGA : Small gestational age

SGOT : Serum glutamate oxaloacetate transaminase

SGPT : Serum glutamate pyruvate transaminase

Sm : Somatomedins

SpO<sub>2</sub> : Oxygen saturation level

STOP-ROP : Supplemental theraputic oxygen for prethreshold Retinopathy of

prematurity

TGF : Tumor growth factor

TGF-B : Tumor growth factor-beta

TNF : Tumor necrosis factor

VEGF : Vascular endothelial growth factor

VEGFR : Vascular endothelial growth factor receptor

VLBW : Very low birth weight

VPF : Vascular permeability factor

Wt : Weight

Wt at exam : Weight at examination

# ABSTRACT

#### **ABSTRACT**

Relation of Vascular Endothelial Growth Factor and Insulin Like Growth Factor-1 to the Development of Retinopathy in Premature Infants

<u>Background:</u> Survival of premature infants in Egypt has been increased in the past few years due to advances in antenatal and neonatal care. This has resulted in a population of infants at high risk of developing retinopathy of prematurity (ROP).

<u>Objective</u>: To evaluate the role of cytokines (Insulin Like Growth Factor-1 "IGF-1" and Vascular Endothelial Growth Factor "VEGF") in serum of premature infants as possible diagnostic markers for ROP and to assess the risk factors for the occurrence and severity of ROP such as birth weight, gestational age, oxygen therapy ...etc.

Methods: Eighty three premature neonates who were admitted to the neonatal intensive care unit (NICU) of Almaza charity neonatal care unit in Cairo were included in this study. They were classified into two groups: those developing ROP (n = 34) and those without ROP (n=49). The ROP group was subdivided to: mild cases (those with stages I and II ROP) and severe cases (those with stages III and V ROP). All babies were examined during their stay in the NICU by the attending staff and also ophthalmic examination was performed during incubation to detect ROP. We obtained serum from each infant at 4 to 6 weeks postnatal age for estimation of IGF-1 and VEGF levels.

**Results**: Analysis of various risk factors for development of ROP showed that small gestational age (GA), low birth weight, prolonged incubation duration, oxygen therapy, respiratory distress syndrome (RDS) and neonatal jaundice were significant risk factors for ROP, while regarding severity of ROP, neonates having respiratory distress syndrome and those with small head circumference were found to be at higher risk of developing severe ROP. Univariate statistical analysis revealed that low IGF-1 and high VEGF serum levels can be useful as indicators in ROP screening but as regards severity they were not predictive markers.

<u>Conclusions</u>: IGF-1 and VEGF serum levels in premature infants could be useful indicators in ROP screening. Elevated VEGF serum level helps to predict the probability of suffering from the illness.

**Key words**: IGF-1, VEGF, retinopathy of prematurity, risk factors.

# INTRODUCTION

#### INTRODUCTION

Retinopathy of prematurity has been identified in 1984 by the Cryo-ROP cooperative group, as a retinal vasoproliferative condition that evolves into five stages. Alongside these stages, other destructive changes also occur inside the eye. The destructive activity is known as "plus disease". The signs of plus disease include: engorgement and tortuosity of the posterior pole retinal vessels, iris vessels engorgement, pupil rigidity and vitreous haze (*Cryo-ROP*, 2001).

The blood vessels in the retina of premature and/or low birth weight infants are immature and underdeveloped. Following delivery, the blood vessels continue to grow and spread throughout the retina. These abnormal blood vessels are fragile and can leak scarring the retina and pulling it out of position leading to retinal detachment (*Stout and Stout, 2003*). Retinopathy of prematurity is an important cause of childhood blindness worldwide (*Brian and Neil, 2009*).

Various risk factors to which the neonates are exposed, i.e. oxygen therapy, apnea, anemia, etc... may aggravate the insult to which the under developed or premature eye is exposed to (*Kim et al.*, 2004).

It has been proposed that vasculogenesis is the result of complex interactions between growth factors (cytokines like IGF-1 and VEGF) produced both locally and systemically which stimulate or inhibit differentiation, proliferation, migration, and maturation of endothelial cells. This process is incriminated in the development of ROP (*Villegas et al.*, 2006).

IGF-I is critical to normal retinal vascular development, and its deficiency is associated with the lack of vascular growth that sets the stage for subsequent hypoxia-driven proliferative ROP. In addition, linking IGF-I and VEGF, it was found that IGF-I receptor activation controls maximum VEGF activation of the endothelial cell survival pathway. Low IGF-I might be used to predict later development of ROP (*Lofqvist et al.*, 2006).

Findings indicate that VEGF, in addition to its function as an angiogenesis factor, may also act as a survival factor for newly formed capillaries in the developing retina and suggest an important role for VEGF in the pathogenesis of human ROP (*Smith*, 2008).

# **Aim of The Study:**

- 1. We aimed to evaluate the role of cytokine levels (IGF-1 and VEGF) in serum of premature infants as possible diagnostic markers for ROP.
- 2. We also aimed to analyze other factors which may act as risk factors for occurrence and severity of ROP like birth weight and gestational age.